Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04414189 · ClinicalTrials.gov registry record
Clinical Validation of HostDx Sepsis™ on NanoString; a Prospective Observational Validation Trial
A clinical trial of Sepsis, sponsored by Inflammatix.
- Completed
- Registry status
- 200
- Enrollment target
- 1
- Study location
NCT04414189: Completed study of Sepsis, sponsored by Inflammatix.
NCT04414189 is a study of Sepsis that has completed, run by Inflammatix. The registered enrollment target is 200 participants, below the 6,562-participant average among 90 other Sepsis trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04414189, a study of Sepsis, has completed, sponsored by Inflammatix.
- COMPLETED
- Registry status
- 200 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will analyze HostDx Sepsis results from whole blood samples collected from patients with suspected sepsis or at risk for sepsis in the surgical ICU
Primary Outcome
Percentage of correctly identified patients with bacterial and/or viral infections using HostDx Sepsis compared to clinical adjudications using routine clinical, laboratory, and other findings
Conditions Studied
Interventions
- DIAGNOSTIC_TEST HostDx Sepsis
Study Locations (1)
Florida
- University of Florida College of Medicine - Gainesville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2020-06-07 |
| Est. Completion | 2021-10-19 |
What the finished NCT04414189 record still lists
NCT04414189 is an observational study that tracks outcomes without assigning an intervention. The registered 200 participants enrollment target is mid-sized for trials with a published cap, below the 6,562-participant average among 90 other Sepsis trials with a reported enrollment target (97% lower).
The record links to 1 condition, with Sepsis appearing as the primary indexed condition, and to 1 intervention - of which HostDx Sepsis is the first listed.
NCT04414189 reports a single indexed study location in Florida.
Frequently Asked Questions
What is clinical trial NCT04414189 about?
NCT04414189 is a clinical study titled "Clinical Validation of HostDx Sepsis™ on NanoString; a Prospective Observational Validation Trial". This study will analyze HostDx Sepsis results from whole blood samples collected from patients with suspected sepsis or at risk for sepsis in the surgical ICU
What is the current status of trial NCT04414189?
This trial is currently completed. The enrollment target is 200 participants. The study started on 2020-06-07. Estimated completion is 2021-10-19.
What conditions does trial NCT04414189 study?
This clinical trial studies the following conditions: Sepsis.
What interventions are being tested in trial NCT04414189?
The interventions under investigation include: HostDx Sepsis (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT04414189?
This trial is sponsored by Inflammatix, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04414189 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Sepsis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04414189's enrollment target sits among peer trials
200 42nd of 90 higher than 46 of 90 other Sepsis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Sepsis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
The APS Phenotyping Study
RECRUITING
-
Senolytics To slOw Progression of Sepsis (STOP-Sepsis) Trial
RECRUITING · Phase 2
-
Early Versus Late Adjunctive Vasopressin in Septic Shock
RECRUITING · Phase 4
-
Renin Angiotensin Aldosterone System In Septic Kids
RECRUITING
-
The RightCall: Implementing a Sepsis Diagnostic Toolkit to Improve Pediatric Diagnosis in ED Transfer Calls
RECRUITING · NA
-
External Drainage of Thoracic Duct Lymph to Reduce Inflammatory Cytokines in Septic Shock Patients
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00107289 · 200 participants · Phase 2
Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma
- NCT00109174 · 200 participants · NA
MRS Measurement of Glutamate and GABA Metabolism in Brain
- NCT00177268 · 200 participants
Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research
- NCT00493688 · 200 participants
A Study to Determine Whether Perioperative Energy Dynamics Correlates With Postoperative Outcomes
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI